Supreme Court questions ₹27,000 MRP on cancer drug priced at ₹2,700 to retailers
The Supreme Court has sought the Centre’s response on wide drug-price mark-ups, generic prescribing and access through Jan Aushadhi Kendras. The case could sharpen scrutiny of non-scheduled medicine pricing and procurement under Ayushman Bharat.
What happened
National Pharmaceutical Pricing Authority (NPPA) · The Supreme Court questioned a cancer drug’s ₹27,000 MRP versus ₹2,700 retailer price, pressing the Centre on
Key facts
- ₹27,000 MRP
- ₹2,700 price to retailer (PTR)
- 10-fold price difference
- DPCO 2013
- around 1,000 scheduled drugs
Why this matters
Prepare for tighter scrutiny of non-scheduled drug mark-ups by expanding generic substitution, transparent pricing and Jan Aushadhi-linked sourcing.
What to watch
- Supreme Court direction seeking a time-bound Centre/NPPA response, committee formation or disclosure of manufacturer-to-retailer pricing.
- NPPA notices, ceiling-price additions, trade-margin rationalization proposals or investigations into oncology drug mark-ups.
- Health Ministry action on mandatory generic prescribing, pharmacy substitution rules or e-prescription standards.
- Union Budget or health-scheme announcements expanding Jan Aushadhi outlets, oncology formulary coverage or Ayushman Bharat drug procurement.
- Tender volumes and awarded prices for oncology generics under central and state procurement programs.